Emily M LaFrance1, Nicholas C Glodosky1, Marcel Bonn-Miller2, Carrie Cuttler3. 1. Washington State University, Department of Psychology, P.O. Box 644820, Pullman, WA, USA, 99164-4820. 2. The University of Pennsylvania Perelman School of Medicine, Department of Psychiatry, 3535 Market Street, Suite 500, Philadelphia, PA 19104. 3. Washington State University, Department of Psychology, P.O. Box 644820, Pullman, WA, USA, 99164-4820. Electronic address: carrie.cuttler@wsu.edu.
Abstract
BACKGROUND: Many individuals use cannabis to manage symptoms of post-traumatic stress disorder (PTSD), and evidence indicates that the endocannabinoid system represents a viable target for treating these symptoms. METHOD: Data from 404 medical cannabis users who self-identified as having PTSD were obtained from Strainprint®, a medical cannabis app that patients use to track changes in symptoms as a function of different strains and doses of cannabis across time. This sample collectively used the app 11,797 times over 31 months to track PTSD-related symptoms (intrusive thoughts, flashbacks, irritability, and/or anxiety) immediately before and after inhaling cannabis. Latent change score models were used to examine changes in symptom severity and predictors of these changes (gender, dose, cannabis constituents, time). Multilevel models were used to explore long-term consequences of repeatedly using cannabis to manage these symptoms. RESULTS: All symptoms were reduced by more than 50% immediately after cannabis use. Time predicted larger decreases in intrusions and irritability, with later cannabis use sessions predicting greater symptom relief than earlier sessions. Higher doses of cannabis predicted larger reductions in intrusions and anxiety, and dose used to treat anxiety increased over time. Baseline severity of all symptoms remained constant across time. LIMITATIONS: The sample was self-selected, self-identified as having PTSD, and there was no placebo control group. CONCLUSIONS: Cannabis provides temporary relief from PTSD-related symptoms. However, it may not be an effective long-term remedy as baseline symptoms were maintained over time and dose used for anxiety increased over time, which is indicative of development of tolerance.
BACKGROUND: Many individuals use cannabis to manage symptoms of post-traumatic stress disorder (PTSD), and evidence indicates that the endocannabinoid system represents a viable target for treating these symptoms. METHOD: Data from 404 medical cannabis users who self-identified as having PTSD were obtained from Strainprint®, a medical cannabis app that patients use to track changes in symptoms as a function of different strains and doses of cannabis across time. This sample collectively used the app 11,797 times over 31 months to track PTSD-related symptoms (intrusive thoughts, flashbacks, irritability, and/or anxiety) immediately before and after inhaling cannabis. Latent change score models were used to examine changes in symptom severity and predictors of these changes (gender, dose, cannabis constituents, time). Multilevel models were used to explore long-term consequences of repeatedly using cannabis to manage these symptoms. RESULTS: All symptoms were reduced by more than 50% immediately after cannabis use. Time predicted larger decreases in intrusions and irritability, with later cannabis use sessions predicting greater symptom relief than earlier sessions. Higher doses of cannabis predicted larger reductions in intrusions and anxiety, and dose used to treat anxiety increased over time. Baseline severity of all symptoms remained constant across time. LIMITATIONS: The sample was self-selected, self-identified as having PTSD, and there was no placebo control group. CONCLUSIONS: Cannabis provides temporary relief from PTSD-related symptoms. However, it may not be an effective long-term remedy as baseline symptoms were maintained over time and dose used for anxiety increased over time, which is indicative of development of tolerance.
Authors: Dorina V Pinkhasova; Laura E Jameson; Kendra D Conrow; Michael P Simeone; Allan Peter Davis; Thomas C Wiegers; Carolyn J Mattingly; Maxwell C K Leung Journal: Curr Res Toxicol Date: 2021-03-01
Authors: Marcel O Bonn-Miller; Sue Sisley; Paula Riggs; Berra Yazar-Klosinski; Julie B Wang; Mallory J E Loflin; Benjamin Shechet; Colin Hennigan; Rebecca Matthews; Amy Emerson; Rick Doblin Journal: PLoS One Date: 2021-03-17 Impact factor: 3.240
Authors: Sarah Gerhardt; Katharina Eidenmueller; Sabine Hoffmann; Nina K Bekier; Patrick Bach; Derik Hermann; Anne Koopmann; Wolfgang H Sommer; Falk Kiefer; Sabine Vollstädt-Klein Journal: Front Psychiatry Date: 2022-04-14 Impact factor: 5.435